These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 27365052)
1. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas. Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052 [TBL] [Abstract][Full Text] [Related]
2. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma. Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313 [TBL] [Abstract][Full Text] [Related]
4. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases. Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230 [TBL] [Abstract][Full Text] [Related]
5. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Kwon JS; Abrams J; Sugimoto A; Carey MS Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450 [TBL] [Abstract][Full Text] [Related]
6. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917 [TBL] [Abstract][Full Text] [Related]
7. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital. Prueksaritanond N; Chantape W J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study. Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570 [TBL] [Abstract][Full Text] [Related]
9. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. Papadia A; Bellati F; Ditto A; Bogani G; Gasparri ML; Di Donato V; Martinelli F; Lorusso D; Benedetti-Panici P; Raspagliesi F Ann Surg Oncol; 2015 Dec; 22(13):4204-10. PubMed ID: 25777095 [TBL] [Abstract][Full Text] [Related]
11. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus. Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927 [TBL] [Abstract][Full Text] [Related]
12. The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study. Cakir C; Kilic F; Kilic C; Tokgozoglu N; Ersak B; Ayhan S; Akar S; Yuksel D; Korkmaz V; Boran N; Toptas T; Kimyon Comert G; Ureyen I; Tasci T; Turkmen O; Moraloglu Tekin O; Ustun Y; Turan T J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102063. PubMed ID: 33453448 [TBL] [Abstract][Full Text] [Related]
13. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394 [TBL] [Abstract][Full Text] [Related]
14. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855 [TBL] [Abstract][Full Text] [Related]
15. Uterine papillary serous carcinoma: patterns of failure and survival. Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700 [TBL] [Abstract][Full Text] [Related]
16. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654 [TBL] [Abstract][Full Text] [Related]
17. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period". Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641 [TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723 [TBL] [Abstract][Full Text] [Related]
19. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]